Pulmonary toxicity secondary to procarbazine

Tallat Mahmood; Raja Mudad

doi:10.1097/00000421-200204000-00018

Pulmonary toxicity secondary to procarbazine

Tallat Mahmood, Raja Mudad

Research output: Contribution to journal › Article

20 Scopus citations

Abstract

Procarbazine is a chemotherapy methylating agent that has been used in combination with other drugs, perhaps most successfully in the treatment of Hodgkin's disease. There are several side effects that it is commonly associated with; however, it has only rarely been reported to cause lung injury. The resulting pneumonitis may be severe and irreversible. There are eight reported cases in the literature. Here, we report another such case.

Original language	English (US)
Pages (from-to)	187-188
Number of pages	2
Journal	American Journal of Clinical Oncology: Cancer Clinical Trials
Volume	25
Issue number	2
DOIs	https://doi.org/10.1097/00000421-200204000-00018
State	Published - Apr 20 2002
Externally published	Yes

Keywords

Lung injury
Procarbazine

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1097/00000421-200204000-00018

Fingerprint Dive into the research topics of 'Pulmonary toxicity secondary to procarbazine'. Together they form a unique fingerprint.

Cite this

Mahmood, T., & Mudad, R. (2002). Pulmonary toxicity secondary to procarbazine. American Journal of Clinical Oncology: Cancer Clinical Trials, 25(2), 187-188. https://doi.org/10.1097/00000421-200204000-00018

@article{c8d92aadbe044675a302587f0295e2b5,

title = "Pulmonary toxicity secondary to procarbazine",

abstract = "Procarbazine is a chemotherapy methylating agent that has been used in combination with other drugs, perhaps most successfully in the treatment of Hodgkin's disease. There are several side effects that it is commonly associated with; however, it has only rarely been reported to cause lung injury. The resulting pneumonitis may be severe and irreversible. There are eight reported cases in the literature. Here, we report another such case.",

keywords = "Lung injury, Procarbazine",

author = "Tallat Mahmood and Raja Mudad",

year = "2002",

month = apr,

day = "20",

doi = "10.1097/00000421-200204000-00018",

language = "English (US)",

volume = "25",

pages = "187--188",

journal = "American Journal of Clinical Oncology",

issn = "0277-3732",

publisher = "Lippincott Williams and Wilkins",

number = "2",

}

TY - JOUR

T1 - Pulmonary toxicity secondary to procarbazine

AU - Mahmood, Tallat

AU - Mudad, Raja

PY - 2002/4/20

Y1 - 2002/4/20

N2 - Procarbazine is a chemotherapy methylating agent that has been used in combination with other drugs, perhaps most successfully in the treatment of Hodgkin's disease. There are several side effects that it is commonly associated with; however, it has only rarely been reported to cause lung injury. The resulting pneumonitis may be severe and irreversible. There are eight reported cases in the literature. Here, we report another such case.

AB - Procarbazine is a chemotherapy methylating agent that has been used in combination with other drugs, perhaps most successfully in the treatment of Hodgkin's disease. There are several side effects that it is commonly associated with; however, it has only rarely been reported to cause lung injury. The resulting pneumonitis may be severe and irreversible. There are eight reported cases in the literature. Here, we report another such case.

KW - Lung injury

KW - Procarbazine

UR - http://www.scopus.com/inward/record.url?scp=0036221166&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036221166&partnerID=8YFLogxK

U2 - 10.1097/00000421-200204000-00018

DO - 10.1097/00000421-200204000-00018

M3 - Article

C2 - 11943900

AN - SCOPUS:0036221166

VL - 25

SP - 187

EP - 188

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 2

ER -